Effect of (Neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage II/III breast cancer
British Journal of Cancer, 05/25/2012
Aft RL et al. – ZOL administered with chemotherapy may improve DFS and OS in a subset of BC patients with ER negative tumours.
Methods- Disease-free survival (DFS; secondary end point) and overall survival (OS; tertiary end point) were evaluated in 119 women with stage II/III BC randomised to intravenous ZOL 4?mg every 3 weeks for 1 year or no ZOL (control) starting with the first chemotherapy cycle.
- At 61.9 months’ median follow-up, there was no significant difference in recurrence or survival between study arms.
- However, time to recurrence or death (DFS) was significantly different between subgroups defined by oestrogen receptor (ER) status (interaction P=0.010 for DFS and 0.025 for OS).
- Hazard ratios (HRs) for disease recurrence and death were significantly less among patients with ER-negative (ER?) tumours who received ZOL vs no ZOL (DFS: HR=0.361, 95% confidence interval (CI) 0.148, 0.880; OS: HR=0.375, 95% CI 0.143, 0.985).
